Actio Biosciences

Executive Summary

Actio Biosciences is a pre-clinical stage biotechnology company leveraging advances in genetics and precision medicine to develop therapies targeting shared biology between rare and common diseases. By integrating expertise in genetics, drug discovery, and data sciences, the company aims to identify and validate high-impact targets that address both rare conditions with high unmet need and larger patient populations in common indications. Founded in 2019 and headquartered in San Diego, Actio operates at the intersection of rare disease genetics and broader therapeutic applicability, a strategy that potentially derisks development and expands market opportunities. The company's approach is exemplified by its focus on causal genetic variants, which increase the probability of clinical success and offer clear patient stratification paths.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination for rare disease program60% success
• H1 2026Presentation of preclinical proof-of-concept data at a major conference70% success
• 2026Series A financing round to support IND-enabling studies50% success